

Ascleitis brings Former MSD Global VP on board

01 March 2019 | News

Ascleitis appoints Former MSD Global Vice President Dr. Zhengqing Li as Chief Medical Officer and President of R&D Greater China



Ascleitis Pharma Inc., an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, has announced that Dr. Zhengqing Li joins Ascleitis as Chief Medical Officer and President of R&D Greater China, reporting to Jinzi J. Wu, PhD., Founder, Chairman and CEO of Ascleitis.

Dr. Li joins Ascleitis from MSD China, where he served as Global Vice President and General Manager of R&D Center China since 2011. He spent the early part of his tenure building MSD China into a fully integrated development organization with more than 600 employees. Under Dr. Li's leadership, MSD China has been responsible for the successful approvals of more than 20 product filings. Led by Dr. Li, between 2017 and 2018, more than ten products were approved in China including Keytruda, Zepatier, Isentress, HPV vaccines (Gardasil and Gardasil 9), Rotateq, Bridion, Nuvaring, and an additional Noxafil indication.

Dr. Li has more than 20 years experience in drug research and development including 15 years in the United States and 8 years in China. Prior to MSD, Dr. Li was Vice President and Head of Clinical Research at BMS China from 2010 to 2011. Dr. Li served as Executive Director of Global Biometric Science at BMS USA from 2006 to 2010. He contributed to clinical development and regulatory success of multiple products in the United States during his tenure with Pfizer and Procter & Gamble pharmaceuticals.